Powered by

Kane Biotech Positions DispersinB® for Wound Care treatment in United States: Applies for U.S. Army Medical Research Funding and renews commitment to Rutgers University

Jan 17, 2019 - GlobeNewswire
Board and Executive Moves

WINNIPEG, Manitoba, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the "Corporation" or "Kane Biotech"), announced today the kick-off of their new human health strategy. Efforts will be focused on development of a wound care hydrogel containing Kane's patented enzyme DispersinB®. Marc Edwards, Chief Executive Officer of Kane Biotech, stated, "I believe DispersinB® could be a technology platform with a variety of applications in various fields. With DispersinB...